Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition, often associated with obesity and type 2 diabetes. Understanding its pathogenesis, diagnosis, and treatment is crucial for managing this global health concern.
NAFLD is characterized by excessive hepatic fat accumulation not due to alcohol consumption. It is a multifactorial disease, with insulin resistance and metabolic syndrome playing pivotal roles. The 'two-hit' hypothesis suggests that the first 'hit' involves accumulation of triglycerides in the liver, followed by a second 'hit' of increased oxidative stress leading to inflammation and fibrosis.
NAFLD is often asymptomatic and discovered incidentally during imaging studies. Liver function tests may show elevated aminotransferases. Ultrasound, CT, and MRI can detect hepatic steatosis, but liver biopsy remains the gold standard for diagnosing NAFLD and differentiating it from non-alcoholic steatohepatitis (NASH).
Management of NAFLD primarily focuses on lifestyle modifications including weight loss and increased physical activity. Pharmacological interventions are considered for patients with NASH or fibrosis. These include vitamin E, pioglitazone, and more recently, drugs targeting specific pathways involved in NAFLD pathogenesis, such as obeticholic acid and elafibranor. Liver transplantation is considered for end-stage liver disease.
NAFLD is a complex disease with a multifaceted pathogenesis. Its diagnosis often requires a high degree of clinical suspicion and appropriate use of diagnostic modalities. Advanced treatment approaches are being developed, targeting the specific mechanisms involved in the disease process. As our understanding of NAFLD continues to evolve, so too will our approach to its management, promising better outcomes for patients afflicted with this condition.
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
Glioblastoma treatment breakthrough shows promise
3.
Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?
4.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
5.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
3.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation